Editors' ChoicePharmacology

OutRANKing osteosarcoma

Sci. Signal.  15 Dec 2015:
Vol. 8, Issue 407, pp. ec373
DOI: 10.1126/scisignal.aae0552

Osteosarcoma is the most common primary bone cancer, and it can be difficult to treat, especially in patients with metastatic disease. Chen et al. developed a series of genetically engineered mouse models of osteosarcoma and used these models to dissect the role of receptor activator of nuclear factor κB ligand (RANKL) signaling in the progression of this disease. Denosumab, an antibody against RANKL that is already used in patients with some bone diseases, was effective in mouse models of osteosarcoma, thus is a viable candidate for future testing in human patients.

Y. Chen, M. A. Di Grappa, S. D. Molyneux, T. D. McKee, P. Waterhouse, J. M. Penninger, R. Khokha, RANKL blockade prevents and treats aggressive osteosarcomas. Sci. Transl. Med. 7, 317ra197 (2015). [Abstract]